ROS1融合变体的分子与临床特征:融合伴侣和断裂点的明确作用
该研究从基于DNA的二代测序队列中检索81例ROS1重排病例,结合RT-PCR、RNA测序和免疫组化分析融合伴侣与ROS1基因组断裂点及其与ROS1-TKI疗效的关系。结果显示ROS1高表达与主要断裂点和经典融合伴侣显著相关,一线TKI治疗的NSCLC患者中intron 33和34断裂点者PFSR显著优于intron 32和罕见位置者。结论提示经典融合伴侣联合intron 33/34断裂点可能是ROS1-TKI获益的最佳预测因素。
要点
- ROS1高表达与主要断裂点及经典融合伴侣显著相关(P<0.001)。
- 一线TKI治疗的NSCLC中intron 33/34断裂点PFSR优于intron 32和罕见位置(80% vs 33.3% vs 0%,P<0.001)。
- 至少一个主要断裂点或经典伴侣者PFSR优于双罕见伴侣且非主要断裂点者(50.4% vs 0%,P<0.001)。
核心结论
- 经典融合伴侣联合ROS1 intron 33和34断裂点可能是ROS1-TKI获益的最佳预测因素。
- 精确表征ROS1断裂点变异可能对ROS1重排癌症的患者分层具有重要意义。
研究设计与样本
- 从基于DNA的二代测序临床队列中检索81例ROS1重排病例。
- 进行RT-PCR、RNA测序和免疫组化染色等综合分析,并将数据与ROS1-TKI临床反应相关联。
主要发现
- 鉴定出经典及约20种罕见融合伴侣,ROS1断裂发生在12个罕见外显子/内含子区域及主要断裂点。
- ROS1高表达与主要断裂点和经典伴侣显著相关,低表达与罕见断裂点和非经典伴侣相关(P<0.001)。
- intron 32断裂点病例排除外显子33以产生框内融合,经典融合伴侣强烈偏好intron 33至intron 32断裂点(P<0.001)。
- 一线TKI治疗的NSCLC患者中,intron 33和34断裂点者PFSR为80%,intron 32为33.3%,罕见位置为0%(P<0.001)。
- 至少一个主要断裂点或经典伴侣者PFSR为50.4%,双罕见伴侣且非主要断裂点者为0%(P<0.001)。
关键数值与推荐
- 一线TKI治疗的NSCLC患者中,ROS1 intron 33和34断裂点者PFSR为80%,intron 32为33.3%,罕见位置为0%(P<0.001)。
- 至少一个主要断裂点或经典伴侣者PFSR为50.4%,双罕见伴侣且非主要断裂点者为0%(P<0.001)。
- ROS1高表达与主要断裂点和经典伴侣显著相关,低表达与罕见断裂点和非经典伴侣相关(P<0.001)。
- 经典融合伴侣强烈偏好intron 33至intron 32断裂点(P<0.001)。
临床怎么用
- 对ROS1重排癌症患者进行精确的ROS1断裂点和融合伴侣表征,以辅助ROS1-TKI治疗的患者分层。
- 优先关注经典融合伴侣及intron 33/34断裂点作为ROS1-TKI获益的预测指标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: ROS1-targeted tyrosine kinase inhibitors (TKIs) are the standard treatment for ROS1-rearranged cancers. We here investigated the therapeutic significance of multiple fusion partners and variable ROS1 genomic breakpoints. METHODS: We retrieved 81 ROS1-rearranged cases from a clinical DNA-based next generation sequencing cohort and performed comprehensive analyses, including reverse transcription-polymerase chain reaction, RNA sequencing and immunohistochemistry staining. The obtained data were correlated with the clinical responses to ROS1-TKIs. RESULTS: ROS1 fusions with canonical and ∼20 rare fusion partners were identified. ROS1 breaks occurred at rare 12 exon/intron regions together with major breakpoints. High ROS1 expression correlated significantly with major breakpoints and canonical partners and low expression associated with rare breakpoints and non-canonical partners (P < 0.001). Cases with an intron 32 ROS1 breakpoint involved exclusion of exon 33 to generate an in-frame fusion, and canonical fusion partners showed a strong preference for an intron 33 to intron 32 breakpoint (P < 0.001). Significantly better progression-free survival rates (PFSR) were observed among first-line TKI-treated NSCLC patients with ROS1 breakpoints in introns 33 and 34, compared with intron 32 and rare locations (80 %, 33.3 %, and 0 %, respectively; P < 0.001). Patients with at least one major breakpoint or canonical partner also showed significantly better PFSR compared to those with both rare partners and non-major breakpoints (50.4 % vs 0 %, P < 0.001). CONCLUSIONS: Canonical fusion partners with introns 33 and 34 of ROS1 may be the most optimal predictors for ROS1-TKI benefit. Precise characterization of the variants in terms of ROS1 breakpoints could be important for patient stratification in ROS1-rearranged cancers.
引用
- Jeong JS, Shin Y, Yoon S, et al. Molecular and Clinical characteristics of ROS1 Fusion Variants in ROS1-rearranged Cancers: A Defined Role of Fusion Partners and Breakpoints of ROS1. Eur J Cancer. 2025. PMID: 41205256. doi:10.1016/j.ejca.2025.116091
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。